1TABATA M,YOSHIDA M,IZUMI T,et al.Retrospective analysis of elderly patients＞or=60 years of age with acute leukemia[J].Rinsho Ketsueki,1998,39:176-184
2SCHAICH M,ILLMER T,AULITZKY W,et al.SHG AML96 Study Group.Intensified double induction therapy with high dose mitoxantrone,etoposide,m-amsacrine and high dose Ara-C for elderly acute myeloid leukemia patients aged 61～65 years[J].Haematologica,2002,87:808-815.
3BAIA,KOJIMA H,HORI M,et al.Priming with G-CSF effectively enhances low-dose Ara-C induced in vivo apoptosis in myeloid leukemia cells[J].Exp Hematol,1999,27:259-265.
4SAITO K,FURUSAWA S,YAMADA K,et al.Comparison of low-dose cytosine arabinoside and aclarubicin in combination with granulocyte colony-stimulating factor to intermediate-dose cytosine arabinoside and mitoxantrone with or without etoposide in the treatment of relapsed acute myeloid leukemia[J].Rinsho Ketsueki,1995,36:165-174.
5Saito K.Low-dose cytosine arabinoside and aclarubicin in combination with granulocyte colony-stimulating factor for the treatment of relapsed acute myeloid leukemia[].Rinsho Ketsueki.1996
6Bai A,Kojima H,Hori M,et al.Priming with G-CSF effectively enhanceslow-dose Ara-C-induced in vivo apoptosis in myeloid leukemia cells[].Experimental Hematology.1999
7Katagiri T,Miyazawa K,Nishimaki J,et al.Combination ofgranulocyte colony-stimulating factor and low-dose cytosinearabinoside further enhances myeloid differentiation in leukemiacells in vitro[].Leukemia and Lymphoma.2000
